Bristol-myers Squibb Compnay

Britsol-myers Squibb Company

Brian E Fink

Ashvinikumar V Gavai

Yufen Zhao

Ping Chen

Wen-Ching Han

Harold A Mastalerz

Libing Chen

Gregory D Vite

Lalgudi S Harikrishnan

Derek J Norris

Soong-Hoon Kim

Dharmpal S Dodd

John S Tokarski

Liqi He

Muthoni G Kamau

Zheming Ruan

Lan-Ying Qin

Robert Michael Borzilleri

Wayne D Vaccaro

Ashok Vinayak Purandare

George V Delucca

Daniel O'Malley

Claude A Quesnelle

Honghe Wan

Yong Zhang

Kurt Zimmermann

Jayakumar Sankara Warrier

Christine M Tarby

Amy C Hart

Patrice Gill

Tram N Huynh

Steven J Walker

Xiaopeng Sang

Guifen Zhang

Walter Lewis Johnson

Jennifer Inghrim

Litai H Zhang

John F Kadow

James Aaron Balog

Raj N Misra

Francis Lee

Gopikishan Tonukunuru

Andrew James Nation

Peter Kinam Park

R Michael Lawrence

Edward H Ruediger

Kyoung S Kim

Mark George Saulnier

Scott Hunter Watterson

Hai-Yun Xiao

Mark E Salvati

Steven P Seitz

Weifang Shan

Audris Huang

Jay A Markwalder

Ellen K Kick

Andrew J Tebben

Liping Zhang

Hasibur Rahaman

Andrew Forrest Donnell

Balaji Seshadri

Bin Chen

Victor R Guarino

Daniel O'malley

Francis Y Lee

Litai Zhang

The present invention is directed to compounds of the formula wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Agonists of ROR GAMMAt

The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Cyclic dinucleotides as anticancer agents

The present invention is directed to compounds of the formula (I), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders. 

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2;R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention. 

TGF beta receptor antagonists

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2; R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

TGF&#x3b2; receptor antagonist

The invention relates generally to compounds that modulate the activity of TGFBETA R-1 and TGFBETA R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

The invention relates generally to compounds that modulate the activity of TGF&#x3b2;R-1 and TGF&#x3b2;R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

TGF&#x3b2;R antagonists

The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Imidazotriazinecarbonitriles useful as kinase inhibitors

Disclosed are compounds of Formula (I): (Formula (I)) wherein: Ris &#x2014;CHCHCF; Ris &#x2014;CHCHCHF, &#x2014;CHCFCH, &#x2014;CHCHCF, &#x2014;CHCH(CH)CF, &#x2014;CHCHCFCH, (Formulae (II), (III), (IV), (V) or (VI): Ris H or &#x2014;CH; Ring A is phenyl or pyridinyl; and R, R, R, R, y, and z are defined herein. Also disclosed are methods of using such compounds to inhibit the Notch receptor, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as cancer. 

Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds

Growing community of inventors

Yardley, PA, United States of America

Brian E Fink